1 Unstoppable Growth Stock Heading to $2 Trillion by 2030

The group of $1 trillion market cap stocks is tiny, and pharmaceutical giant Eli Lilly (NYSE: LLY) isn’t a member yet, though it is within striking distance at about $820 billion.

However, the drugmaker’s prospects look so strong that not only should it soon join the $1 trillion club, but it could even be a member of the more exclusive $2 trillion club by 2030. Here’s why.

The tirzepatide tailwind

What’s considered “solid” growth in revenue for a corporation? The answer depends on the industry. Top-line increases in the high single-digit and low double-digit percentages are pretty good for pharmaceutical companies, particularly large and well-established ones. Anything above that is, obviously, even better.

Let’s look at a chart of Eli Lilly’s quarterly revenue growth during the past year:

LLY Revenue (Quarterly YoY Growth) Chart

Notice that the growth rate never dropped below 24%.

Why is Eli Lilly performing so well? In a word: tirzepatide. That’s the active ingredient in Mounjaro, a diabetes medicine, and Zepbound, which treats obesity. It was first approved in 2022.

In the second quarter, Lilly’s tirzepatide-based medications generated a little more than $4 billion in sales. The overwhelming majority of drugs never generate $4 billion annually throughout their years of patent protection. Clearly, Eli Lilly has something special on its hands, and it’s still just getting started.

There are at least two indications for which tirzepatide has already passed phase 3 clinical trials but isn’t approved yet. The first is obstructive sleep apnea in obese patients. The second is decreasing the risk of developing type 2 diabetes in overweight or obese patients who are prediabetic. There are several more areas in which tirzepatide is being tested, including metabolic dysfunction-associated steatohepatitis, an area with a high unmet need.

So, Eli Lilly’s financial results will continue to be impressive through 2030 — largely thanks to tirzepatide, which will help send its stock price and market cap much higher. But that doesn’t tell the whole story.